3-FEA: Difference between revisions
>Unity Grammatics |
>Unity m Grammatics |
||
Line 24: | Line 24: | ||
Notably, it has been demonstrated that "compared to the unsubstituted ethylamphetamine, 3-fluoroethamphetamine is a weaker releaser of noradrenaline, but a stronger releaser of both dopamine and serotonin, and produced the strongest reinforcing effects in animal studies out of a range of 3-substituted amphetamine derivatives tested, despite not being the most potent dopamine releaser"<ref>Tessel RE, Woods JH. Structural relationship between meta-substituted N-ethylamphetamines and self-administration in rhesus monkeys. ''Pharmacologist'' 1974;16:142.</ref><ref>Tessel RE, Rutledge CO. Specificity of release of biogenic amines from isolated rat brain tissue as a function of the meta substituent of N-ethylamphetamine derivatives. ''The Journal of Pharmacology and Experimental Therapeutics'' 1976;15:142.</ref><ref>Tessel RE, Woods JH. Substituted N-ethylamphetamine self injection responding in the rhesus monkey: structure-activity relationships. ''The Journal of Pharmacology and Experimental Therapeutics'' 1978; 2: 274–81.</ref> | Notably, it has been demonstrated that "compared to the unsubstituted ethylamphetamine, 3-fluoroethamphetamine is a weaker releaser of noradrenaline, but a stronger releaser of both dopamine and serotonin, and produced the strongest reinforcing effects in animal studies out of a range of 3-substituted amphetamine derivatives tested, despite not being the most potent dopamine releaser"<ref>Tessel RE, Woods JH. Structural relationship between meta-substituted N-ethylamphetamines and self-administration in rhesus monkeys. ''Pharmacologist'' 1974;16:142.</ref><ref>Tessel RE, Rutledge CO. Specificity of release of biogenic amines from isolated rat brain tissue as a function of the meta substituent of N-ethylamphetamine derivatives. ''The Journal of Pharmacology and Experimental Therapeutics'' 1976;15:142.</ref><ref>Tessel RE, Woods JH. Substituted N-ethylamphetamine self injection responding in the rhesus monkey: structure-activity relationships. ''The Journal of Pharmacology and Experimental Therapeutics'' 1978; 2: 274–81.</ref> | ||
This indicates that 3-FEA effectively increases the levels of all the three major [[monoamine neurotransmitters]] dopamine, norepinephrine, and serotonin in the brain by binding to and partially [[Reuptake inhibitor|blocking the transporter proteins]] that normally clear those molecules from the [[synaptic cleft]] after they have fulfilled their function of conducting a neural impulse. This allows these molecules to accumulate within core regions of the brain to extra-endogenous levels, resulting in a combination of [[Relaxation|relaxing], [[stimulating]], motivational and physically and cognitively [[euphoria|euphoric]] effects associated with [[entactogen]]ic [[substituted amphetamines]] like [[MDMA]] or other fluorinated amphetamines like [[4-FA]].{{citation needed}} | This indicates that 3-FEA effectively increases the levels of all the three major [[monoamine neurotransmitters]] dopamine, norepinephrine, and serotonin in the brain by binding to and partially [[Reuptake inhibitor|blocking the transporter proteins]] that normally clear those molecules from the [[synaptic cleft]] after they have fulfilled their function of conducting a neural impulse. This allows these molecules to accumulate within core regions of the brain to extra-endogenous levels, resulting in a combination of [[Relaxation|relaxing]], [[stimulating]], motivational and physically and cognitively [[euphoria|euphoric]] effects associated with [[entactogen]]ic [[substituted amphetamines]] like [[MDMA]] or other fluorinated amphetamines like [[4-FA]].{{citation needed}} | ||
==Subjective effects== | ==Subjective effects== |